Anti-VEGF antibody conjugated CdHgTe quantum dots as a fluorescent probe for imaging in living mouse

Pang, Lili; Cui, Hongjing; Liu, Yu; Zhong, Wenying

doi:10.1016/j.jlumin.2016.01.006

Cited by 9 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were attempts to use antibody-conjugated QDs for cancer cell imaging and tracking. 49,50 We previously showed that the antibody-QD complex not only recognizes its specific antigen, but also is engulfed inside the cells, while antibodies conjugated with commonly used organic fluorophore FITC remained on the cell membrane. 50 Although these results show promising potential of antibody-nanoparticle complexes to be used in both diagnostics and therapy, the success of such therapy is limited due to lack of tumor-specific antigens.…”

Section: Discussionmentioning

confidence: 99%

Skin-derived mesenchymal stem cells as quantum dot vehicles to tumors

Dapkutė¹,

Steponkienė²,

Bulotienė³

et al. 2017

IJN

View full text Add to dashboard Cite

Purpose Cell-mediated delivery of nanoparticles is emerging as a new method of cancer diagnostics and treatment. Due to their inherent regenerative properties, adult mesenchymal stem cells (MSCs) are naturally attracted to wounds and sites of inflammation, as well as tumors. Such characteristics enable MSCs to be used in cellular hitchhiking of nanoparticles. In this study, MSCs extracted from the skin connective tissue were investigated as transporters of semiconductor nanocrystals quantum dots (QDs). Materials and methods Cytotoxicity of carboxylated CdSe/ZnS QDs was assessed by lactate dehydrogenase cell viability assay. Quantitative uptake of QDs was determined by flow cytometry; their intracellular localization was evaluated by confocal microscopy. In vitro tumor-tropic migration of skin-derived MSCs was verified by Transwell migration assay. For in vivo migration studies of QD-loaded MSCs, human breast tumor-bearing immunodeficient mice were used. Results QDs were found to be nontoxic to MSCs in concentrations no more than 16 nM. The uptake studies showed a rapid QD endocytosis followed by saturating effects after 6 h of incubation and intracellular localization in the perinuclear region. In vitro migration of MSCs toward MDA-MB-231 breast cancer cells and their conditioned medium was up to nine times greater than the migration toward noncancerous breast epithelial cells MCF-10A. In vivo, systemically administered QD-labeled MSCs were mainly located in the tumor and metastatic tissues, evading most healthy organs with the exception being blood clearance organs (spleen, kidneys, liver). Conclusion Skin-derived MSCs demonstrate applicability in cell-mediated delivery of nanoparticles. The findings presented in this study promise further development of a cell therapy and nanotechnology-based tool for early cancer diagnostics and therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Skin-derived mesenchymal stem cells as quantum dot vehicles to tumors

Dapkutė¹,

Steponkienė²,

Bulotienė³

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…In the pathogenesis of ocular diseases like exudative AMD, DME, NVG, and ROP, VEGF-induced neoangiogenesis, mediated by insulin-like growth factor-1 (IGF-1), plays a central role [86] . VEGF elicits several angiogenic responses, including endothelial cell proliferation, stimulation of cell migration, enhancement of vascular permeability, promotion of neovascularization, and participation in various physiological processes [87] . Within the mammalian VEGF family, five members exist: VEGFA, VEGFB, VEGFC, VEGFD, and placental growth factor (PIGF).…”

Section: Vegf-related Drugsmentioning

confidence: 99%

Advancements in Neovascular Ophthalmopathy: Therapeutic Strategies and Future Prospects

Zhang,

Lu,

et al. 2023

Preprint

View full text Add to dashboard Cite

Abnormal ocular angiogenesis is a key factor in the development of many blinding ocular diseases, including wet age-related macular degeneration (wAMD), diabetic macular oedema (DME), pathologic myopia with choroidal neovascularization (PM-CNV), and neovascular glaucoma (NVG). The development of anti-neovascular drugs and ocular drug delivery systems (DDS) offers more possibilities for the treatment of neovascular eye diseases. In addition to anti-vascular endothelial growth factor (anti-VEGF) agents, the discovery of other anti-angiogenic targets, such as somatostatin, endostatin and pigment epithelium-derived factor (PEDF), has been a boon to patients with poor anti-VEGF efficacy and led to a reduction in the adverse effects of long-term VEGF inhibition. Gene therapy is currently a very promising approach for the treatment of neovascular ophthalmopathy. The rapid development of gene therapy and the potential for viral vector-mediated gene delivery to achieve sustained expression of anti-vascular substances at the lesion site will mitigate the risks associated with frequent intraocular injections for patients. This review provides an overview of several neovascular ophthalmopathies, discusses the use of anti-vascular therapeutic agents and common DDS, and summarizes treatment strategies and future perspectives for neovascular ophthalmopathy.

show abstract

“…Carbon nanoparticles (carbon dots, CDs) opened new opportunities in the field of nanomedicine due to their excitation wavelength-dependent photoluminescence emission, dispersibility in water, biocompatibility, and high cell membrane permeability . Surface functional groups, such as hydroxyl, amino, and carboxylic groups, are amenable for CD conjugation with drugs. − Furthermore, CDs exhibit high resistance to photobleaching. , Fluorescent CDs have been conjugated to antibodies and anticancer drugs − and mixed with VEGF . Covalent linking of CDs to VEGF while still preserving its angiogenic performance would enable noninvasive detection of this growth factor during angiogenesis in injured tissues; however, it has not been reported.…”

Section: Introductionmentioning

confidence: 99%

Carbon Dots Conjugated with Vascular Endothelial Growth Factor for Protein Tracking in Angiogenic Therapy

et al. 2020

View full text Add to dashboard Cite

One of the challenges of using growth factors for tissue regeneration is to monitor their biodistributions and delivery to injured tissues for minimally invasive detection. In the present study, tracking of human vascular endothelial growth factor (VEGF) was achieved by chemically linking it to photoluminescent carbon dots (CDs). Carbon dots were synthesized by the hydrothermal method and, subsequently, conjugated with VEGF using carbodiimide coupling. ELISA and western blot analysis revealed that VEGF-conjugated CDs preserve the binding affinity of VEGF to its antibodies. We also show that VEGF-conjugated CDs maintain the functionality of VEGF for tube formation and cell migration. The VEGF-conjugated CDs were also used for in vitro imaging of human umbilical vein endothelial cells. The results of this work suggest that cell-penetrating VEGF-conjugated CDs can be used for growth factor protein tracking in therapeutic and tissue engineering applications.

show abstract

Anti-VEGF antibody conjugated CdHgTe quantum dots as a fluorescent probe for imaging in living mouse

Cited by 9 publications

References 25 publications

Skin-derived mesenchymal stem cells as quantum dot vehicles to tumors

Skin-derived mesenchymal stem cells as quantum dot vehicles to tumors

Advancements in Neovascular Ophthalmopathy: Therapeutic Strategies and Future Prospects

Carbon Dots Conjugated with Vascular Endothelial Growth Factor for Protein Tracking in Angiogenic Therapy

Contact Info

Product

Resources

About